The Society

The European Atherosclerosis Society (EAS) was founded in 1964, to “advance and exchange knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease”. The Society’s main activities are focused on four main areas:

the dissemination of up-to-date knowledge of the pathophysiology underlying atherogenic dyslipidemia and premature atherosclerosis
the prevention, diagnosis and treatment of atherosclerotic vascular disease in non-diabetic and diabetic subjects
the promotion of cutting-edge basic and clinical research in the field of atherosclerosis and related metabolic diseases such as Metabolic Syndrome and Type 2 Diabetes
the support, promotion, and organization of scientific Congresses and Workshops both within and outside Europe on topics related to atherosclerosis in its widest sense. These include:

lipid, lipoprotein and cholesterol metabolism

vascular biology

mechanisms underlying atherosclerosis and clinical cardiovascular events, particularly myocardial infarction

cerebro- and peripheral vascular disease

genetics of atherosclerotic vascular diseases

plaque imaging modalities

pharmacotherapy of lipid disorders

prevention of atherosclerotic vascular disease

The EAS has close links with National Atherosclerosis Societies throughout Europe, and with other active European organizations, notably the European Society of Cardiology (ESC). At an international level, EAS contributes to the worldwide activities of the Inter-national Atherosclerosis Society (IAS), to which it is formally linked. In addition, EAS is active in supporting joint sessions at the annual congresses of organizations such as IAS, ESC, the International Diabetes Federation (IDF), the International Chair on Cardiometabolic Risk (ICCR), and the Asian-Pacific Society of Atherosclerosis and Vascular Diseases (ASPAVD).

Future Horizons

With the dramatic worldwide progression of the pandemic of metabolic diseases including obesity and diabetes, and premature atherosclerosis and cardiovascular dis-ease on the one hand, and with the aging of the European population on the other, atherosclerosis has become a major health concern.

In this light, EAS has joined forces with other societies and groups actively involved in this field. Our common goals are to prevent the disease and to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diag-nosis and therapy of atherosclerosis. The EAS is Europe’s resource for expertise in these areas, as well as in inherited disorders of lipid metabolism associated with high cardiovascular risk. With our partners, we will promote European prevention projects and approach both public and private sec-tors for support.